Desmopressin and bleeding risk after percutaneous kidney biopsy
Related Experiment Video
Updated: Jan 3, 2026
Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
Ambarish Athavale1, Hemant Kulkarni2, Cagil D Arslan3
1Division of Nephrology, Cook County Health, 1950 W. Polk Street, 5th Floor, Chicago, IL, 60605, USA. aathavale@cookcountyhhs.org.
Insights
Desmopressin use before kidney biopsy increases bleeding risk in most patients. It may benefit only those with very high creatinine levels, but evidence is limited.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Desmopressin is sometimes used to prevent bleeding after kidney biopsy.
- Evidence for its effectiveness is limited, particularly in patients with impaired kidney function.
Purpose of the Study:
- To evaluate the efficacy of desmopressin in reducing bleeding complications after percutaneous kidney biopsy.
Main Methods:
- A retrospective cohort study included 269 patients undergoing percutaneous kidney biopsy.
- Outcomes included hemoglobin drop, hematoma, hematuria, transfusion, or angiography.
- Propensity score adjustment was used to control for confounding factors.
Main Results:
- Desmopressin administration was associated with increased odds of post-biopsy bleeding (OR 3.88).
- Creatinine levels significantly influenced bleeding risk.
- Desmopressin decreased bleeding risk in patients with serum creatinine ≥1.8 mg/dL but increased it in those with <1.8 mg/dL.
Conclusions:
- Routine use of desmopressin before percutaneous kidney biopsy is not recommended for low-risk patients.
- Desmopressin should be reserved for carefully selected high-risk patients, potentially those with very elevated creatinine.
Background:
Desmopressin is used to reduce bleeding after kidney biopsy but evidence supporting its use is weak, especially in patients with elevated creatinine. The present study was undertaken to evaluate efficacy of desmopressin in reducing bleeding after percutaneous kidney biopsy.
Methods:
Retrospective cohort study. 269 of 322 patients undergoing percutaneous kidney biopsy between January 1, 2014 and January 31, 2018 were included. Patients had normal bleeding time, platelet count and coagulation profile. Primary outcome was defined as composite of hemoglobin drop ≥1 g/dL, hematoma on post biopsy ultrasound, gross hematuria, erythrocyte transfusion or angiography to stop bleeding. Association of desmopressin with outcomes was assessed using linear (for continuous variables) and logistic (for binary variables) regression models. Propensity score was used to minimize potential confounding.
Results:
Desmopressin was administered to 100/269 (37.17%) patients. After propensity score adjustment patients who received desmopressin had increased odds of post biopsy bleeding [OR 3.88 (1.95-7.74), p < 0.001]. Creatinine at time of biopsy influenced bleeding risk; gender, emergent vs elective biopsy, obesity, AKI, diabetes, hypertension or bleeding time did not influence bleeding risk. Administration of desmopressin to patients with serum creatinine ≥1.8 mg/dL decreased bleeding risk [OR 2.11 (95% CI 0.87-5.11), p = 0.09] but increased bleeding risk when serum creatinine was < 1.8 mg/dL (OR 9.72 (95% CI 2.95-31.96), p < 0.001).
Conclusion:
Desmopressin should not be used routinely prior to percutaneous kidney biopsy in patients at low risk for bleeding but should be reserved for patients who are at high risk for bleeding.
Related Concept Videos
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:19Imaging Studies VII: Vascular Imaging
01:24Hemodialysis II: Procedure and Complications
01:26Kidney Transplant II: Surgical Procedure
01:26Cardiac Catheterization IV: Nursing Management